{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yoshida Y"],"funding":["National Institute of General Medical Sciences of the National Institutes of Health","the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Scholar","the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Scholar","NIGMS NIH HHS"],"pagination":["784"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9555705"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Objective</h4>The impact of comorbidities and biomarkers on COVID-19 severity vary by sex but have not yet been verified in population-based studies. We examined the association of comorbidities, inflammatory biomarkers, and severe outcomes in men and women hospitalized for COVID-19.<h4>Design</h4>This is a retrospective cohort analysis based on the National COVID Cohort Collaborative (N3C). We included 574,391 adult patients admitted for COVID-19 at hospitals or emergency rooms between 01/01/2020 and 12/31/2021.<h4>Methods</h4>We defined comorbidities at or before the first admission for COVID-19 by Charlson Comorbidity Index (CCI) and CCI components. We used the averaged lab values taken within 15 days before or after the admission date to measure biomarkers including c-reactive prot"],"journal":["BMC infectious diseases"],"pubmed_title":["Sex differences in determinants of COVID-19 severe outcomes - findings from the National COVID Cohort Collaborative (N3C)."],"pmcid":["PMC9555705"],"funding_grant_id":["U54 GM104940","K12HD043451"],"pubmed_authors":["Denson JL","Miele L","Mauvais-Jarvis F","Chu S","Yoshida Y","Fox S","Lovre D","Zu Y"],"additional_accession":[]},"is_claimable":false,"name":"Sex differences in determinants of COVID-19 severe outcomes - findings from the National COVID Cohort Collaborative (N3C).","description":"<h4>Objective</h4>The impact of comorbidities and biomarkers on COVID-19 severity vary by sex but have not yet been verified in population-based studies. We examined the association of comorbidities, inflammatory biomarkers, and severe outcomes in men and women hospitalized for COVID-19.<h4>Design</h4>This is a retrospective cohort analysis based on the National COVID Cohort Collaborative (N3C). We included 574,391 adult patients admitted for COVID-19 at hospitals or emergency rooms between 01/01/2020 and 12/31/2021.<h4>Methods</h4>We defined comorbidities at or before the first admission for COVID-19 by Charlson Comorbidity Index (CCI) and CCI components. We used the averaged lab values taken within 15 days before or after the admission date to measure biomarkers including c-reactive prot","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T22:35:48.478Z","creation":"2025-04-04T22:35:48.478Z"},"accession":"S-EPMC9555705","cross_references":{"pubmed":["36224551"],"doi":["10.1186/s12879-022-07776-7"]}}